X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (66) 66
index medicus (61) 61
hematology (56) 56
life sciences (55) 55
male (49) 49
female (48) 48
middle aged (40) 40
adult (34) 34
aged (32) 32
cancer (31) 31
oncology (23) 23
leukemia (22) 22
human health and pathology (21) 21
leukemia, lymphocytic, chronic, b-cell - drug therapy (19) 19
aged, 80 and over (18) 18
treatment outcome (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
young adult (15) 15
chemotherapy (14) 14
cyclophosphamide (14) 14
prognosis (14) 14
adolescent (13) 13
disease-free survival (13) 13
hemic and lymphatic diseases (13) 13
retrospective studies (13) 13
rituximab (13) 13
patients (12) 12
chronic lymphocytic leukemia (11) 11
survival (11) 11
therapy (11) 11
[ sdv ] life sciences [q-bio] (10) 10
analysis (10) 10
lymphomas (10) 10
minimal residual disease (10) 10
mutation (10) 10
[ sdv.can ] life sciences [q-bio]/cancer (9) 9
[sdv.can]life sciences [q-bio]/cancer (9) 9
[sdv]life sciences [q-bio] (9) 9
cll (9) 9
fludarabine (9) 9
immunology (9) 9
infectious diseases (9) 9
lymphoma (9) 9
[sdv.mhep.hem]life sciences [q-bio]/human health and pathology/hematology (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
biopsy (8) 8
care and treatment (8) 8
chronic lymphatic leukemia (8) 8
diagnosis (8) 8
recurrence (8) 8
research (8) 8
risk factors (8) 8
vidarabine - analogs & derivatives (8) 8
antineoplastic agents - therapeutic use (7) 7
chlorambucil (7) 7
chronic lymphocytic leukaemia (7) 7
classification (7) 7
clinical trials (7) 7
cyclophosphamide - administration & dosage (7) 7
health aspects (7) 7
leptin (7) 7
non-hodgkins-lymphoma (7) 7
[ sdv.mhep.hem ] life sciences [q-bio]/human health and pathology/hematology (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
b-cell lymphoma (6) 6
chemical sciences (6) 6
cyclophosphamide - therapeutic use (6) 6
efficacy (6) 6
france (6) 6
france - epidemiology (6) 6
genetic aspects (6) 6
genotype (6) 6
immunotherapy (6) 6
leukemia, lymphocytic, chronic, b-cell - genetics (6) 6
leukemia, lymphocytic, chronic, b-cell - mortality (6) 6
leukemia, lymphocytic, chronic, b-cell - pathology (6) 6
lymphatic leukemia (6) 6
medical prognosis (6) 6
medicine (6) 6
mesh : humans (6) 6
microbiology (6) 6
ofatumumab (6) 6
open-label (6) 6
remission induction (6) 6
stem-cell transplantation (6) 6
survival rate (6) 6
abridged index medicus (5) 5
acute myeloid-leukemia (5) 5
age factors (5) 5
chemoimmunotherapy (5) 5
child (5) 5
children (5) 5
cohort studies (5) 5
cyclophosphamide - adverse effects (5) 5
disease (5) 5
elderly (5) 5
expression (5) 5
fatigue (5) 5
follow-up studies (5) 5
gene expression (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 11/2017, Volume 44, Issue 12, pp. 2034 - 2041
PurposeWe examined whether FDG PET can be used to predict outcome in patients with lymphoblastic lymphoma (LL).MethodsThis was a retrospective post hoc... 
Clinical trial | Chemotherapy | F-FDG | Prognostic factors | Lymphoblastic lymphoma | PET/CT | Acute lymphatic leukemia | Data acquisition | Cut-off | Leukemia | Lymphocytes T | Metabolism | Lymphoma | Patients | Survival | Medical prognosis | Glycolysis | Lymphomas | Adults | Positron emission tomography | Tumors
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 06/2017, Volume 56, Issue 6, pp. 635 - 647
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2016, Volume 34, Issue 6, pp. 572 - 580
Journal Article
10. Full Text Central nervous system involvement by malignant cells is a rare complication of Waldenström macroglobulinemia, and this clinicopathological entity is referred to as the Bing-Neel syndrome. There is currently no consensus on the diagnostic criteria, therapeutic approaches and response evaluation for this syndrome. In this series, we retrospectively analyzed 44 French patients with Bing-Neel syndrome. Bing-Neel syndrome was the first manifestation of Waldenström macroglobulinemia in 36% of patients. When Waldenström macroglobulinemia was diagnosed prior to Bing-Neel syndrome, the median time interval between this diagnosis and the onset of Bing-Neel syndrome was 8.9 years. This study highlights the possibility of the occurrence of Bing-Neel syndrome without any other evidence of progression of Waldenström macroglobulinemia. The clinical presentation was heterogeneous without any specific signs or symptoms. Biologically, the median lymphocyte count in the cerebrospinal fluid was 31/mm(3). Magnetic resonance imaging revealed abnormalities in 78% of the cases. The overall response rate after first-line treatment was 70%, and the overall survival rate after the diagnosis of Bing-Neel syndrome was 71% at 5 years. Altogether, these results suggest that Bing-Neel syndrome should be considered in the context of any unexplained neurological symptoms associated with Waldenström macroglobulinemia. The diagnostic approach should be based on cerebrospinal fluid analysis and magnetic resonance imaging of the brain and spinal axis. It still remains difficult to establish treatment recommendations or prognostic factors in the absence of large-scale, prospective, observational studies
Haematologica, ISSN 0390-6078, 11/2015, Volume 100, Issue 12, pp. 1587 - 1594
Central nervous system involvement by malignant cells is a rare complication of Waldenström macroglobulinemia, and this clinicopathological entity is referred... 
Life Sciences | Hematology | Human health and pathology
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2019, Volume 25, Issue 8, pp. 2483 - 2493
Purpose: Biological explanation for discrepancies in patient-related response to chemotherapy depending on the underlying oncogenic events is a promising... 
CYTOGENETIC ABNORMALITIES | SYNTHETASE EXPRESSION | CELLS | ONCOLOGY | STANDARD-RISK | ACUTE LYMPHOBLASTIC-LEUKEMIA | GENE-EXPRESSION | RESISTANCE | ADULTS | HOX11L2 EXPRESSION | CHILDREN | Life Sciences | Immunology | Adaptive immunology | Cancer
Journal Article
American Journal of Hematology, ISSN 0361-8609, 06/2015, Volume 90, Issue 6, pp. 511 - 514
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2014, Volume 166, Issue 3, pp. 390 - 400
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, p. 1DUMMY
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 12/2017, Volume 139, Issue 49, pp. 17994 - 18002
Designing systems that merge the advantages of heterogeneous catalysis, enzymology, and molecular catalysis represents the next major goal for sustainable... 
PROTEIN CRYSTALS | MECHANISM | GREEN CHEMISTRY | CHLOROHYDRINS | NICKEL-BINDING | IRON | CLEAVAGE | CHEMISTRY, MULTIDISCIPLINARY | IMMOBILIZATION | C-H | METALLOENZYME | Proteins | Analysis | Crystallization | Redox potential | Chemical properties | Iron oxides | Carbon compounds | Chemical Sciences | Catalysis
Journal Article